TrialTumori2023

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).

Giuseppe Procopio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.